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Gene therapy vectors derived from the human parvovirus AAV-2 (adeno-associated virus type 2) have gained attention owing to a unique combination of attractive features. Wild-type AAV-2 is nonpathogenic in humans and naturally defective, requiring coinfection with a helpervirus (eg adenovirus) for a productive infection. 1 Recombinant AAV-2 can infect both dividing and nondividing cells in vitro and in vivo [2] [3] [4] [5] [6] and have the potential for sitespecific integration into chromosome 19. [7] [8] [9] Long-term expression of heterologous genes transduced by rAAV has been observed in a variety of human cells and tissues, such as muscle, 10, 11 lung, 12 central nervous system, [13] [14] [15] retina 16 and liver. 17 An important prerequisite for the testing of AAV-2 vectors in preclinical and clinical studies is the accurate and reliable titration of the recombinant virus particles. Precise information on rAAV titers is not only crucial for the careful planning and execution of such studies, but also for comparing results amongst laboratories. In brief, presently available methods for rAAV titration can be divided into biological and physical assays. Biological assays rely on infection of cultured cells followed by events that depend on the biological functionality of the Correspondence: JA Kleinschmidt Received 4 November 1998; accepted 8 March 1999 rAAV vector, ie either replication of the recombinant genomes in cells in the presence of AAV-2 and adenoviral helper functions, or expression of the transduced heterologous gene. [18] [19] [20] These two types of assay yield titers of infectious or transducing particles, respectively. In contrast, physical methods are independent of biological functions of the recombinant viruses. Typically, viral DNA is extracted from the rAAV particles via enzymatic digestion of the capsids and quantified using serially diluted plasmid DNA bearing the transgene as standard. 18 , 21 The number of DNA-containing particles is then calculated assuming that each virion carries one singlestranded DNA molecule with a defined size.
In spite of being rather simple in concept and execution, all common rAAV titration methods display distinct disadvantages. Biological methods are highly dependent on the properties of the vectors and the particular assay conditions, which are prone to differ among various laboratories. For example, quantification of functional transducing rAAV particles is influenced by the cell type used, the promotor driving the transgene or the transgene itself. 22, 23 Another crucial parameter is the helper virus, which can increase the efficiency of rAAVmediated gene transduction and consequently the functional rAAV titers by three orders of magnitude. [23] [24] [25] Similarly, physical methods to measure DNA-containing particles involve a number of steps, in particular exhaus-tive enzymatic treatment of the virions, which are possibly inconsistent in different laboratories and thus may provoke variable results. As a consequence, rAAV titers as well as the ratios of physical to functional particles, which are considered as important indices for the quality of rAAV preparations, show a great variation, thus making direct comparisons of results from different studies quite difficult. Moreover, whilst quantification of encapsidated viral genomes is usually considered to yield total particle titers, this method of course fails to detect empty virions which are devoid of DNA. In fact, there is a lack of methods for quantification of total numbers of physical rAAV particles, ie the sum of assembled packaged or empty virions. Yet, in view of the possibility that AAV-2 capsid proteins can elicit a humoral host immune response, methods to determine exact numbers of total AAV-2 capsids in a given rAAV preparation are urgently needed.
In this report, we present a novel AAV-2 capsid ELISA that fits in this gap by allowing the rapid and reliable quantification of assembled, empty or full, AAV-2 particles. Given this property, the ELISA not only permits a better characterization of rAAV preparations, but also a more profound investigation of the AAV-2 genome packaging process in general. Indeed, we obtained and present first evidence that encapsidation of recombinant AAV-2 genomes occurs rather inefficiently and can be a limiting step for rAAV vector production.
A sandwich ELISA allowing the quantification of assembled AAV-2 particles was developed based on a previously described monoclonal antibody, A20, that specifically binds to assembled AAV-2 capsids, but not to single capsid proteins. 26 A scheme depicting further details is shown in Figure 1a . To calibrate the ELISA, stocks of empty AAV-2 capsids or full AAV-2 virions were used as particle standards. The empty capsids were prepared from 293 cells infected with a recombinant adenovirus which expressed the AAV-2 cap gene under the control of a human CMV promoter (rAdVP) and purified as described. 27 To determine the maximum number of AAV-2 capsids in this empty particle standard, the protein concentration of an aliquot was determined using a commercial protein quantification assay (BioRad, Mü nchen, Germany). Assuming a stoichiometry of the three VP proteins of 1:1:10 in the assembled capsid (Figure 1b) , an approximate number of 1.2 × 10 12 capsids/ml was deduced from the total protein concentration of 7.8 ng/l measured for the empty particle standard. In addition, the capsid number was determined by mixing equal amounts of the empty particle stock and an adenovirus 5 (Ad-5) stock of known titer (5 × 10 10 pfu/ml) and by counting the AAV-2 and Ad-5 particles in 40 randomly chosen electron microscopy pictures of this mixture (Figure 1c) . A 34.6-fold excess of AAV-2 capsids relative to Ad-5 capsids was counted, and since the Ad-5 stock contained 2.3 × 10 11 capsids/ml (determined according to Ref. 28), the particle standard was calculated to have 8 × 10 12 empty AAV-2 capsids/ml (assuming that AAV-2 and Ad-5 particles bind equally well to the EM grids). Likewise, a preparation of CsClpurified, UV-inactivated wild-type AAV-2 particles was established as full particle standard, having a similar titer of 7.9 × 10 12 capsids/ml. Serial two-fold dilutions of the empty or full particle standard were used to obtain ELISA titration curves (examples are shown in Figure 1d ). In the experiments reported below, only the linear part of the standard curves, ie the part between optical densities of 0.4 and 1.6 (corresponding to 10 7 to 10 8 particles per 100 l), was used to derive values for unknown samples. The coefficient of variation in this part of the curves was 3-25%, but increased up to 67% at lower optical densities (calculated from 10 standard curves). Therefore, we consider the optical density of 0.4, which corresponds to approximately 10 7 assembled particles per sample, as the quantification limit of the AAV-2 capsid ELISA, while the actual detection limit is somewhat lower (approximately 10 6 particles). This renders the AAV-2 ELISA sensitive enough to be used for titration of any rAAV preparation, assuming an average generation of at least 10 4 assembled particles per cell during rAAV production.
The finding that the curves derived from empty or full particle standard samples with similar titers were nearly identical proved that the ELISA can be applied to the titration of both types of AAV-2 particles. This was expected since the ELISA relies on antibody(A20)-mediated recognition of an epitope which is supposed to be present on any assembled AAV-2 capsid, irrespective of being empty or full. Furthermore, earlier experiments have already shown that the monoclonal antibody A20 recognizes both wild-type and recombinant particles. 20, 26 Thus, the AAV-2 capsid ELISA not only provides a high grade of versatility, but is also highly suitable for standardization between laboratories, as it allows the titration of any type of AAV-2 particle via one invariant protocol.
Finally, spiking experiments were performed to address the question if sample matrix effects would influence the outcome of the ELISA measurement. Aliquots of a stock of purified empty capsids were mixed with different aliquots of cell culture medium, CsCl or MgCl 2 and titrated via ELISA. Except for MgCl 2 at concentrations above 20 mm, particle titers were found to vary less than 20%, which was within the range that could be expected from the variation coefficient of the standard curves (see above). From these findings, it was concluded that ELISA-based titration is not influenced by sample matrix effects.
Following the general characterization of the ELISA, we analyzed how the assembled particle titers obtainable via the ELISA would relate to titers determined by common methods for AAV-2 titration. Therefore, we first prepared a series of wild-type AAV-2 stocks (Table 1) and titrated them via the ELISA to gain numbers of assembled particles. In parallel, these stocks were analyzed via commonly used methods to determine corresponding numbers of DNA-containing, infectious or transducing particles. For details and results see Table 1 . As expected, the assembled particle titers determined via ELISA were always highest, reaching up to approximately 10 12 capsids/ml for the AAV-2 stocks derived from infection, and being only slightly lower for those generated by transfection. Importantly, the titers of DNAcontaining particles were generally two-to four-fold lower than the assembled particle titers. This was clearly in line with the assumption that only a portion of the total particles present in an AAV-2 stock has packaged DNA or is infectious. Assuming that the DNA quantification method yielded reliable DNA-containing particle titers, the data suggest that a minimum of 25 up to 50% of the AAV-2 capsids were packaged or somehow associated with viral genomes. The numbers of infectious or transducing AAV-2 particles were one to three orders of magnitude lower than the numbers of assembled particles and at least 10-fold lower than those of the DNAcontaining particles (Table 1 and Figure 2a-c) .
In the course of these first titration experiments, the AAV-2 ELISA proved to be very reliable. Repeated titration of one distinct AAV-2 stock under consistent conditions (as described in Figure 1a ) gave capsid titers which were highly reproducible. The inter-assay variation was actually found to be less than 20%, which is most likely due to the fact that ELISA-based AAV-2 titration, in contrast to common methods, neither involves steps which are prone to influence the particle measurement, such as prior enzymatic treatment of the virions, nor any biological components, eg cells or a helper virus.
Subsequent experiments aimed at confirming that the ELISA could also be used for the titration of recombinant AAV-2 particles. Table 2 lists a variety of rAAV stocks that were generated and then analyzed in a manner identical to the wild-type AAV-2 stocks. In general, most of the various titers measured for the rAAV stocks prepared using the pDG helper plasmid were several-fold higher than those obtained via transfection and infection of the cells with the p⌬TR helper construct and Ad-5, respectively. This confirms and extends our own previous findings that rAAV production using pDG is more efficient than using a standard Rep-/VP-expressing packaging plasmid. 20 Similar to wild-type AAV-2, the assembled particle titers obtained via the ELISA were highest in each of the rAAV stocks analyzed, being on average only slightly below those calculated for the wild-type virus particles (Tables 1 and 2 ). The numbers of DNA-containing rAAV particles, however, were markedly lower than the particular wild-type AAV-2 titers, resulting in higher average ratios of physical to DNA-containing rAAV particles of approximately 5 up to 60:1. These ratios depended mainly on the vector plasmid used but seemed not to be influenced by the choice of cell line or helper plasmid (Table 2 and Figure 2a-c) . This indicated that, as compared with wild-type AAV-2, fewer capsids were loaded with recombinant genomes, namely a maximum of only Infectious AAV-2 particles were quantified via replication assays essentially as described previously. 20 Briefly, HeLa cells were infected with the AAV-2 samples and Ad-5, incubated for 3 days and lysed. The replicated AAV-2 genomes were blotted on to a Nylon membrane and detected using a radioactively labeled 4.3 kb XbaI fragment from p⌬TR 20 as probe. Titers of infectious particles were deduced from the highest dilution of each sample which gave a positive hybridization signal. d The quantification of DNA-containing AAV-2 particles was performed as described. 18 Briefly, viral DNA was extracted from the AAV-2 particles and blotted on to a Nylon membrane. As DNA standards five-fold serial dilutions of p⌬TR from 5 ng down to 1.6 pg were blotted on to the same membrane. A radioactively labeled XbaI fragment from p⌬TR was hybridized to detect AAV-2 genomes. Hybridization signal intensities were quantified using a phosphoimager, and particle titers were calculated based on the values obtained for the standard samples. e Physical (assembled) particles were measured via the AAV-2 capsid ELISA essentially as described in the legend to Figure 1 . Up to 22 samples were titrated together on one A20-coated microtiter plate. For each plate, a separate standard curve was made using an empty particle standard. Particle titers for the various AAV-2 samples were derived from those dilutions which gave absorption values that were within the linear range of the standard curves. 20% (eg pTRUFlacZ) down to 1.7% (pAVJE). The numbers of infectious or transducing rAAV showed an even stronger decrease not only compared with wild-type AAV-2, but in particular to the rAAV capsid titers, indicating that only a very small portion of less than 0.1% of the assembled rAAV particles were actually infectious or capable of transduction in these assays (Table 2 and Figure 2a-c) .
Caution was taken, however, when interpreting these initial findings which were based on comparisons of capsid and genome numbers. This was because the DNA quantification method used is highly dependent upon a number of parameters and thus possibly yielded DNAcontaining particle titers that were not fully reliable. In particular, it can not be excluded that numbers of DNAcontaining particles were overestimated due to replicated genomes outside the capsids that were protected against DNaseI digestion (eg by Rep or cellular proteins). The preponderance of empty capsids in rAAV stocks thus needed additional confirmation. Therefore, a wild-type AAV-2 and two rAAV(lacZ) stocks were subjected to CsCl density gradient centrifugation and gradient fractions having densities of 1.30 to 1.50 g/cm 3 were analyzed using the same titration methods as before (Figure 2d-f) . The quantification of either DNAcontaining or transducing wild-type AAV-2 particles revealed one distinct peak at a density of 1.40-1.43 g/cm 3 , where full and infectious particles were expected to be found. 18 ,37,38 Importantly, ELISA-based measurement of assembled particles resulted in a peak which was not only the strongest one, but also matched the peaks of the DNA-containing or transducing particles. A second, but smaller culmination of physical particles was found at a density of around 1.33 g/cm 3 , where empty particles were supposed to accumulate. 18, 37, 38 Two conclusions are drawn: firstly, the fact that measurement of capsid concentrations gave two peaks at the expected densities which complemented the data obtained using common titration methods strongly proved that the ELISA is dependable. Second, the appearance of a distinct peak of assembled particles being paralleled by culminations of DNA-containing and transducing particles reinforced the initial finding that a large portion of wildtype AAV-2 virions is actually packaged and capable of transduction.
Analyses of the two rAAV(lacZ) stocks gave distinct peaks for DNA-containing and transducing particles that matched each other, although as compared with wildtype AAV-2, a shift to a higher density of 1.43-1.46 g/cm 3 was noticed. However, ELISA-based titration revealed a predominant peak of assembled rAAV particles at a low density of 1.33-1.36 g/cm 3 , indicating a large portion of Recombinant AAV-2 were prepared via transfection of 293 or 293T cells with equal molar amounts of one of the listed vector plasmids and either p⌬TR or pDG as helper plasmid. 20 Only p⌬TR-transfected cells were additionally infected with Ad-5 (MOI 10). rAAV particles were harvested 2 (pDG) or 3 (p⌬TR) days after transfection. While up to 50% of all rAAV stocks made using the p⌬TR plasmid were contaminated with wild-type AAV-2 (0.001-1%), none of the rAAV stocks derived from pDG contained replication-competent wildtype AAV-2. a pTRUF5 was kindly provided by N Muzyczka, Gene Therapy Center, Gainesville, FL, USA. 33 pTRUFluc was generated by inserting a 2.72 kb SpeI/XhoI fragment from pBL, 34 which encompassed the firefly luciferase cDNA followed by a SV40 polyA site, into XbaI/SaII linearized pTRUF3. 33 pTRUFlacZ resulted from cloning of a 3.49 kb SalI/BamHI fragment from pGEM1-nlslacZ (provided by JeanFrançois Nicolas, Paris), comprising the LacZ cDNA together with a nuclear localization sequence and a SV40 polyA site, into pTRUF3 cut with XhoI and partially digested with BglII. For generation of pACVlacZ, a 3.5 kb NotI LacZ fragment from pCMV␤ 35 was ligated into NotI linearized pACV. Plasmid pACV was constructed by first ligating a 630 bp PstI fragment from pKEX 36 containing a CMV promoter as well as a 900 bp SmaI/BamHI fragment from pKEX comprising a SV40 polyA site into pBluescript KS (Stratagene, Heidelberg, Germany). Next, an EcoRV/BamHI fragment from the resulting plasmid was inserted into XbaI linearized pSSV9 after blunting of both fragments. Plasmids pAVJE and pAVRz6 will be described in detail elsewhere (Kunke et al, manuscript in preparation). Given in parentheses are the sizes of the recombinant AAV-2 genomes including the AAV-2 ITRs. b Transducing rAAV(gfp) particles (derived from pTRUF5) were quantified via FACS analyses of HeLa cells (5 × 10 4 cells per well in a 24-well plate) 24 h after infection with 10-fold serially diluted rAAV(gfp) stocks. The percentage of gfp-expressing cells was calculated and the rAAV(gfp) titers determined based on total cell numbers and sample dilutions. For titration of transducing rAAV(lacZ) particles (from pTRUFlacZ or pACVlacZ), HeLa cells (5 × 10 3 cells per well in a 96-well plate) were infected with 10-fold serially diluted rAAV preparations and overinfected with Ad-5 (MOI 10). 24 h later, the cells were washed with PBS and fixed in 0.25% glutaraldehyde in PBS, pH 7.4. The cells were washed and then incubated with X-gal staining solution (PBS supplied with 1 mg X-gal/ml, 5 mm K 3 Fe(CN) 6 and K 4 Fe(CN) 6 each, 2 mm MgCl 2 ) a 37°C for several hours. Blue stained cells were counted and the rAAV(lacZ) titers calculated based on the sample dilution. c Titration of infectious rAAV particles was done as described for wild-type AAV-2 (see Table 1 ), except that HeLaRC32 cells, which express the AAV-2 Rep and VP proteins upon infection with Ad-5 and thus allow amplification of rAAV genomes, 22 were used. Hybridization was performed using a 685 bp BamHI fragment from pCMVVP 26 containing the CMV promoter that was presented in all rAAV vectors used here. d For titration of DNA-containing rAAV particles see Table 1 ; the BamHI fragment from pCMVVP was used for detection of recombinant AAV-2 genomes. ND, not determined. empty capsids. Vice versa, an ELISA peak matching the majority of DNA-containing and transducing rAAV particles at a density of about 1.44-1.45 g/cm 3 was barely detectable (Figure 2d-f) . A larger portion of empty versus full particles was also observed after CsCl gradient fractionation of rAAV stocks that were generated using the p⌬TR plasmid (data not shown). Taken together, all results clearly confirmed the preponderance of nonpackaged and non-transducing particles in rAAV stocks. Moreover, this finding is also clearly in line with our recently published electron microscopy analysis of rAAV stocks in which the majority of the observed rAAV particles were found to be empty. 20 Two reasons for this phenomenon can be speculated: recombinant AAV-2 genomes could either be replicated less efficiently in cells than wild-type genomes, yielding fewer single stranded DNA molecules ready for encapsidation. Alternatively, recombinant AAV-2 genomes might also be lacking some yet undefined elements required for efficient DNA encapsidation additional to the terminal repeats. However, discriminating between these possibilities would have required additional investigation which was beyond the range of this report.
Irrespective of the exact reasons, the pure finding that rAAV preparations are characterized by an excess of empty capsids is of particular importance with respect to rAAV production. Several reports have recently shown that an efficient rAAV production depends on a strong VP protein expression, 39, 40 which, as demonstrated by others, itself is a prerequisite for a high rate of AAV-2 capsid assembly. 20, 41 Based on these correlations, we finally investigated whether further increasing VP protein expression and thus the rate of AAV-2 capsid assembly during rAAV production would result in a concomitant increase in assembled and functional rAAV particle titers. Therefore, several rAAV stocks were generated via cotransfection of 293 cells with pDG and pTRUFlacZ and by additionally overinfecting the cells with the rAdVP virus (see above). Control rAAV stocks were prepared under identical conditions, but leaving out the rAdVP infection. Titration of the stocks derived from the rAdVP-infected cells revealed a two-to five-fold Table 1 ) Table 2 ). p⌬TR-transfected cells were infected with increase in DNA-containing and only marginal changes of transducing rAAV particle numbers as compared with the control stocks (Figure 3a) . However, the capsid numbers were up to 25-fold increased, indicating the generation of a massive excess of non-packaged and non-transducing assembled particles as a result of the rAdVP infection (Figure 3a) .
. The cells were additionally infected with Ad-5 (MOI 10). Recombinant AAV-2 (right of the broken line) were generated via cotransfection of 293T or 293 (marked with asterisks) cells with p⌬TR or pDG and one of the indicated vector plasmids (see
Similar observations were made when VP protein expression was elevated by transfection of 293T cells with increasing molar amounts of pDG relative to pTRUFlacZ (Figure 3b/c) . A 1:1 molar ratio of helper and vector plasmid resulted in the production of a seven-to eight-fold excess of assembled to DNA-containing particles, while yielding the highest transducing particle titers. As expected, transfection of a five-or 10-fold molar excess of pDG was followed by an elevated production of Rep and VP proteins (in a constant stoichiometry, Figure 3b ) and consequently an increased generation of assembled capsids (as detected via ELISA, Figure 3c ). On the other hand, the numbers of DNA-containing or transducing particle titers slightly declined, which led to increased ratios of assembled to DNA-containing or to transducing particles. After transfection of up to 10-fold lower molar amounts of pDG than pTRUFlacZ, AAV-2 protein expression as well as titers of assembled or transducing particles decreased, and only the numbers of DNAcontaining particles remained constant (Figure 3b/c) . Thus, the excess of assembled to DNA-containing and to a lesser extent, transducing particles was significantly reduced under those conditions, however, the absolute transducing particle titers were also lowest. Similar results were obtained using the 293 cell line except that the absolute particle titers were all several-fold lower (data not shown).
In sum, these two experiments show that VP expression is only limiting for rAAV production until a certain threshold of assembled capsids, ready to get packaged with recombinant genomes, is reached. Rather than improving yields of DNA-containing or transducing particles, further overexpression of VP proteins only results in the excessive production of empty capsids. This is of course highly undesirable since under these conditions host immune responses to VP proteins become more likely. Together these findings again strongly indicate that as yet undefined elements involved in DNA replication or encapsidation, which are missing on common rAAV vectors, but are present on wild-type genomes, are generally limiting rAAV production. With the feasibility of measuring capsid numbers and ratios of empty to full particles given now by the AAV-2 ELISA, future studies should aim at elucidating this obvious block in replication or encapsidation of rAAV genomes. The identification of these elements or mechanisms required for an optimum yield of packaged AAV-2 particles would certainly have a significant impact on the production of rAAV vectors for human gene therapy.
